Wednesday, August 26

Browsing: Outpatient

Survivors

Tocilizumab Supports Outpatient Bispecific Antibody Use in Multiple Myeloma

By NewsCancerMay 31, 20260

A single dose of prophylactic tocilizumab (Actemra) reduced the incidence of cytokine release syndrome (CRS) and supported the community-based outpatient…

Survivors

Moving Bispecifics and Prophylaxis to Outpatient Multiple Myeloma Care

By NewsCancerMay 15, 20260

Following the 2026 National ICE-T Conference in Charlotte, North Carolina, Prerna Mewawalla, MD, spoke with CancerNetwork® about important considerations for…

Diagnosis

Debate Round 1: Should CAR-T Be Given Inpatient or Outpatient?

By NewsCancerApril 1, 20260

Panelists engage in a structured debate on whether CAR T-cell therapy for aggressive large B-cell lymphoma should be administered in…

Treatments

Streamlining CAR T-Cell Care Coordination and Evolving Outpatient Management in Multiple Myeloma

By NewsCancerFebruary 20, 20260

This segment integrates two key aspects of delivering CAR T-cell therapy in multiple myeloma: efficient coordination between community practices and…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Venetoclax/HMA Combo Demonstrates Real-World Efficacy in Unfit AML

All-trans retinoic acid suppresses CD8+ T-cell terminal exhaustion and potentiates anti-PD-1 therapy in glioblastoma

Debate: Class Effect Versus Meaningful Differences Among BCMA Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Browsing: Outpatient

Tocilizumab Supports Outpatient Bispecific Antibody Use in Multiple Myeloma

Moving Bispecifics and Prophylaxis to Outpatient Multiple Myeloma Care

Debate Round 1: Should CAR-T Be Given Inpatient or Outpatient?

Streamlining CAR T-Cell Care Coordination and Evolving Outpatient Management in Multiple Myeloma

Venetoclax/HMA Combo Demonstrates Real-World Efficacy in Unfit AML

All-trans retinoic acid suppresses CD8+ T-cell terminal exhaustion and potentiates anti-PD-1 therapy in glioblastoma

Debate: Class Effect Versus Meaningful Differences Among BCMA Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Exploring The Future of Radiopharmaceutical Therapy in Oncology

Venetoclax/HMA Combo Demonstrates Real-World Efficacy in Unfit AML

All-trans retinoic acid suppresses CD8+ T-cell terminal exhaustion and potentiates anti-PD-1 therapy in glioblastoma

Debate: Class Effect Versus Meaningful Differences Among BCMA Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Exploring The Future of Radiopharmaceutical Therapy in Oncology

Latest Post

Venetoclax/HMA Combo Demonstrates Real-World Efficacy in Unfit AML

All-trans retinoic acid suppresses CD8+ T-cell terminal exhaustion and potentiates anti-PD-1 therapy in glioblastoma

Debate: Class Effect Versus Meaningful Differences Among BCMA Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Subscribe to Updates

What's Hot

Browsing: Outpatient